Current Canadian experience with capecitabine: Partnering with patients to optimize therapy

Cancer Nursing

Volumn 26, Issue 2, 2003, Pages 161-167

  Gerbrecht, Bonnie Mae ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Building patient partnerships; Capecitabine; Hand foot syndrome; Nursing roles; Side effect management

Indexed keywords

CAPECITABINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MITOXANTRONE; PACLITAXEL;

ARTICLE; CANADA; CANCER; CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; EXPERIENCE; FATIGUE; HAND FOOT SYNDROME; HEALTH CARE PERSONNEL; HOME CARE; HUMAN; HUMAN RELATION; NAUSEA; NURSE; PATIENT EDUCATION; PRIORITY JOURNAL; STOMATITIS; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIMETABOLITES, ANTINEOPLASTIC; BENCHMARKING; BREAST NEOPLASMS; CANADA; DEOXYCYTIDINE; HUMANS; MALE; MIDDLE AGED; NURSE'S ROLE; ONCOLOGIC NURSING; SAFETY; TREATMENT OUTCOME;

EID: 0037381437     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002820-200304000-00011     Document Type: Article

References (16)

1. Twelves C, Boyer M, Findlay M, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer. 2001;37:597-604.
2. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol, 2001;19:2282-2292.
3. Blum JL. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist. 2001;6:56-64.
4. Kuhn JG. Fluorouracil and the new oral fluorinated pyrimidines. Ann Pharmacol. 2001;35:217-227.
5. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotberapy. J Clin Oncol, 1997;15:110-115.
6. Diasio RB. Current status of oral chemotherapy for colorectai cancer. Oncology. 2001;15:16S-20S.
7. Bissett D, Ahmed F, McLeod H, Cassidy J. Oral fluoropyrimidines in the treatment of colorectal cancer. J Clin Oncol. 2000;12:240-245.
8. Hoffman La-Roche Limited. Xeloda Prescribing Information; July 5, 2000.
9. Royce ME, Hoff PM, Pazdur R. Progress in colorectal cancer chemotherapy: how far have we come, how far to go? Drugs Aging. 2000;3:201-216.
10. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet. 2001;40:85-104.
11. Roche. Xeloda: product monograph. In: Compendium of Pharmaceuticals and Specialties. 35th ed. Ottawa: Canadian Pharmacists Association; 2000:1748-1750.
12. Hoffman La-Roche Limited. Xeloda Dosing Information; 2000.
13. Reigner B, Clive S, Cassidy J, et al. Influence of the antacid Maalox on the pharrnacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol. 1999;43:309-315.
14. Mrozek-Orlowski ME, Frye DK, Sanborn HM. Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum. 1999;26:573-762.
15. Dodd MJ, Dibble SL, Miaskowski C, et al. Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90:39-47.
16. Baack BR, Burgdorf WH. Chernotherapy-induced acral erythema. J Am Acad Dermatol. 1991;24:457-461.